ArticleInternational journal of chronic obstructive pulmonary disease2026
Bu-Fei Yi-Shen Formula Alleviates Oxidative Stress and Improves Airway Epithelial Barrier Dysfunction in COPD.
Article in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the potential of Bu-Fei Yi-Shen Formula (BYF) in ameliorating airway epithelial barrier dysfunction in chronic obstructive pulmonary disease (COPD) and to elucidate the underlying mechanisms. Methods: By establishing both in vivo and in vitro models of COPD, this study examined lung function, lung tissue pathology, inflammatory cytokines levels, cellular apoptosis rate, oxidative stress intensity, and TEER. Concurrently, it quantified the expression levels of proteins relevant to apical junctions, apoptosis, and the Nrf2 signaling pathway. These exhaustive analyses were undertaken to decipher the intricate mechanisms by which BYF ameliorates the disruption of airway epithelial barrier integrity in COPD. Results: BYF significantly improved lung function, attenuated lung tissue pathological damage, reduced inflammatory cytokines levels, inhibited cellular apoptosis, upregulated the expression of apical junctional proteins, and alleviated oxidative stress injury in a COPD rat model. In vitro, BYF restored the CSE-induced decreases in TEER values and apical junctional protein expression in BEAS-2B cells, while reducing airway epithelial cell apoptosis apoptosis and oxidative stress injury. Furthermore, BYF counteracted the inhibitory effects of CSE on Nrf2, facilitating the expression of HO-1, a downstream protein of Nrf2. The addition of ML385 exacerbated the apoptosis, oxidative stress, and barrier dysfunction induced by CSE; however, the co-administration of ML385 and BYF reversed the inhibitory effects of ML385. Conclusion: These findings underscore that BYF ameliorates airway epithelial barrier dysfunction in COPD by activating the Nrf2/HO-1 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.